BRD2 and metastatic neoplasm: Next, we evaluated the expression of MD2 in NAT (normal tissues adjacent to the cancerous region), primary (Grade Groups (GG) I–II or GG III-IV), and metastatic tumors (lymph-node, brain, testis).